MCT Pre-Meal Dosing Window for Higher Ketones Without GI Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for administering medium chain triglycerides (MCTs) do not optimize ketone production and often result in gastrointestinal side effects, and the impact of meal timing on ketogenic effects has not been reported.

Innovation Solution

Administering an MCT emulsion to an individual prior to a meal, specifically between 10 to 60 minutes before, to enhance ketone production and minimize gastrointestinal side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If MCTs are administered by oral bolus to increase ketone production, then ketone precursor efficiency is improved, but gastrointestinal side effects worsen

Engineering Contradiction:

Improveketone production efficiencyVSAvoidgastrointestinal side effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering MCTs 10-60 minutes before a meal rather than with or after the meal. This timing allows the MCTs to be absorbed and metabolized to ketones before the meal's presence in the gastrointestinal tract can cause side effects, thus resolving the contradiction between efficient ketone production and gastrointestinal tolerability

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the temporal parameter of MCT administration relative to meal timing. By optimizing the time interval between MCT administration and meal consumption (10-60 minutes before), the patent achieves maximum ketone production while minimizing gastrointestinal side effects, thereby resolving the technical contradiction

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If MCTs are administered with a meal to reduce gastrointestinal side effects, then gastrointestinal tolerability is improved, but ketone production is reduced

Engineering Contradiction:

Improvegastrointestinal side effectsVSAvoidketone production

Core Design Contradiction:

Object-affected harmful factorsVSProductivity

Solution Approach 1:

The patent administers MCTs in advance (10-60 minutes before the meal) rather than concurrently with the meal. This preliminary timing ensures that ketone production occurs before the meal can interfere with absorption or metabolism, thereby maintaining high productivity while avoiding gastrointestinal issues that would result from co-administration

Inventive Principle:

Principle #10Preliminary action

3Productivity

If MCTs are administered too early before a meal, then ketone production is maximized, but the time window for optimal effect is reduced

Engineering Contradiction:

Improveketone production amountVSAvoidoptimal administration window

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent optimizes the temporal parameter by identifying the specific window of 10-60 minutes before meal consumption as optimal for MCT administration. This parameter optimization balances ketone production efficiency with practical timing constraints, achieving maximum benefit without excessive time loss

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach results in the largest amount of blood ketones without GI side effects, with ketone production greater than when administered with a meal, improving conditions such as neurological health, cognitive function, and exercise performance.

Implementation Method 1

They are rapidly digested, and the resultant free medium chain fatty acids (MCFAs) are absorbed efficiently by the portal vein to reach the liver where they are extensively metabolized to ketones

Methodology Applied

Scientific EffectKetogenesis:

Implementation Method 2

BHB and AcA are actively transported to the brain by the monocarboxylic transporter 1 (MCT1), resulting in brain levels directly proportional to their blood concentrations

Methodology Applied

Scientific EffectActive transport:

Data Source

PatentEP3941455B1Methods using administration of medium chain triglycerides (MCT) prior to a meal to increase ketone production from the mcts

Publication Date: 2026.02.25 SOCIETE DES PRODUITS NESTLE SA

Figure 1

AI summary

A method increases production of ketones derived from oral consumption of medium chain triglycerides (MCT) by an individual. The method includes orally administering to the individual a composition containing the MCTs and then subsequently orally administering to the individual a meal at least about ten minutes after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The ketone production is increased relative to ketone production from oral administration of the MCTs and the meal at approximately the same time. The meal can be breakfast. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.